基于SEER数据库的肿瘤直径大于7.0厘米的非小细胞肺癌患者预后分析

目的 区分肿瘤直径>7.0 cm的非小细胞肺癌（NSCLC）患者死亡风险，评估手术及非手术治疗的临床价值。方法 基于SEER数据库收集2010—2015年肿瘤直径>7.0 cm非小细胞肺癌患者数据。寿命表法计算1、2、3年生存率，Kaplan-Meier法绘制生存曲线，单因素及多因素Cox回归模型分析预后影响因素。结果 纳入的5 519例患者1、2、3年累计生存率分别为51.8%、33.0%、25.0%。单因素、多因素Cox回归分析显示肿瘤大小、淋巴结N分期、治疗方式是影响NSCLC的预后独立危险因素（P<0.001）。结论 N0~N1期肿瘤直径>7.0 cm非小细胞肺癌患者，手术治疗有利于患者生存预后。N2期肿瘤直径7.0~9.0 cm组，手术治疗在改善患者预后方面存在优势。N2期肿瘤直径≥9.0 cm组以及N3期患者手术与非手术患者预后方面差异未见统计学意义。姑息治疗不能改善患者预后。

Prognosis Analysis of Non-small Cell Lung Cancer with Diameter over 7.0 cm Based on SEER Database

Objective To analyze the mortality risk and evaluate the curative effects of surgery and nonsurgery on NSCLC with diameter >7.0 cm. Methods We collected the data of NSCLC patients with diameter >7.0 cm from 2010 to 2015 from the SEER database. The 1, 2, 3-year survival rates were analyzed by life table method. Overall survival curve was estimated by Kaplan-Meier method. Univariate and multivariate Cox regression models were used to analyze the independent prognostic factors. Results The 1, 2, 3-year survival rates were 51.8%, 33.0% and 25.0%, respectively. In univariate and multivariate analyses, tumor size, N stage and treatment were the independent prognostic factors (P<0.001). Conclusion Surgery is benefited for the prognosis of stage N0-N1 NSCLC patients with diameter >7.0 cm. And for stage N2 NSCLC patients with diameter 7.0-9.0 cm, surgical treatment has advantages in improving the prognosis. Surgical and non-surgical patients with tumor diameter ≥9.0 cm or lymph node N3 stage have no statistically significant differences in prognosis. In addition, palliative treatment does not improve the prognosis of patients.